Acupuncture for Post COVID-19 Condition (Long COVID) Neuropsychiatric Symptoms

Last updated: November 11, 2024
Sponsor: Hong Kong Baptist University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Covid-19

Treatment

Acupuncture

Clinical Study ID

NCT06633666
2023Cmdevfund
  • Ages 18-80
  • All Genders

Study Summary

In this study, a 12-week pragmatic, randomized, double-blinded clinical trial will be conducted to evaluate the efficacy of acupuncture for the treatment of long Covid neuropsychiatric symptoms and provide reference for clinical non-drug treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • meet the clinical diagnosis of Long COVID by the World Health Organization (WHO),with no neuropsychiatric symptoms 1 year before infection with Covid-19, andcontinue to have at least one neuropsychiatric symptom for 2 months after SARS-CoV-2turned negative 3 months above;

  • aged 12 to 80 years;

  • willing and able to consent, and complete all assessment and study procedures

Exclusion

Exclusion Criteria:

  • patients with a history of chronic neuropsychiatric symptoms;

  • cardiovascular diseases pre-existing to the Covid-19 episode such as arrhythmia,heart failure, myocardial infarction, and patients with cardiac pacemakers;

  • documented pre-existing history of psychiatric illness, including substance abuse;

  • suicidal tendencies (attempted suicide in the 12 months before the study);

  • any chronic or remote neurological disorder (i.e. stroke, head trauma, epilepsy,tumor);

  • those who participated in other clinical trials within one month;

  • pregnant or lactating female patients;

  • have surgery within two months before the study or will have a scheduled surgeryduring the study;

  • acute brain injury or acute encephalopathy from another etiology than Covid-19 (e.g., sepsis, liver or renal failure, alcohol or drug withdrawal, drug toxicity);

  • open-heart cardiac surgery or cardiac arrest during the last 6 months;

  • patients who received acupuncture treatment 1 month before the start of the study;

  • patients who were unable to complete the assessment during screening due to severemental, cognitive, or emotional impairment

Study Design

Total Participants: 160
Treatment Group(s): 1
Primary Treatment: Acupuncture
Phase:
Study Start date:
July 30, 2023
Estimated Completion Date:
April 30, 2026

Study Description

This is a pragmatic, randomized, double-blinded clinical trial on acupuncture for treating neuropsychiatric symptoms in long Covid patients. A total of 160 participants will be diagnosed by a registered Chinese medicine practitioner and randomly assigned to the acupuncture and the control group with a 1:1 ratio. The acupuncture group will receive 24 sessions of interventions during a 12-week treatment duration (2 sessions per week) and will be followed up at week 18. The control group will only receive conventional therapy.

Connect with a study center

  • Linda Zhong

    Kowloon Tong, Kowloon
    Hong Kong

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.